Literature DB >> 27672679

Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C.

Margaret Lashof-Sullivan1, Mark Holland2, Rebecca Groynom1, Donald Campbell1, Andrew Shoffstall1, Erin Lavik3.   

Abstract

According to the CDC, the leading cause of death for both men and women between the ages of 5 and 44 is traumatic injury. Blood loss is the primary cause of death at acute time points post trauma. Early intervention is critical to save lives, and yet there are no treatments to stop internal bleeding that can be deployed in the field. In this work, we developed hemostatic nanoparticles that are stable at high temperatures (50 °C for 7 days) and are still effective at stopping bleeding and improving survival over the one hour time period in a rat liver injury model. These particles are exceptionally simple: PLA-based nanospheres functionalized with PEG terminated with variants of the RGD motif. This simple system can be stored at temperatures up to 50°C and maintain size, shape, and efficacy. The particles lead to a reduction in bleeding and increased acute survival with significance compared to both control particles and saline. Overall, these hemostatic nanoparticles offer an important step towards an immediate intervention in the field to stop bleeding and improve survival.

Entities:  

Keywords:  artificial fibrinogen; artificial platelet; bleeding; blunt trauma; fibrinogen; hemostasis; liver injury; synthetic fibrinogen; synthetic platelet

Year:  2016        PMID: 27672679      PMCID: PMC5034295          DOI: 10.1021/acsbiomaterials.5b00493

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  32 in total

Review 1.  Uses of recombinant factor VIIa in trauma.

Authors:  Deborah M Stein; Richard P Dutton
Journal:  Curr Opin Crit Care       Date:  2004-12       Impact factor: 3.687

2.  Thermal stability of prehospital medications.

Authors:  T D Valenzuela; E A Criss; W M Hammargren; K H Schram; D W Spaite; H W Meislin; J B Clark
Journal:  Ann Emerg Med       Date:  1989-02       Impact factor: 5.721

3.  Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

Authors:  Kenneth David Boffard; Bruno Riou; Brian Warren; Philip Iau Tsau Choong; Sandro Rizoli; Rolf Rossaint; Mads Axelsen; Yoram Kluger
Journal:  J Trauma       Date:  2005-07

4.  The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles.

Authors:  Timothy J Merkel; Kai Chen; Stephen W Jones; Ashish A Pandya; Shaomin Tian; Mary E Napier; William E Zamboni; Joseph M DeSimone
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

5.  Intravenously administered nanoparticles increase survival following blast trauma.

Authors:  Margaret M Lashof-Sullivan; Erin Shoffstall; Kristyn T Atkins; Nickolas Keane; Cynthia Bir; Pamela VandeVord; Erin B Lavik
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 6.  Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations.

Authors:  David S Kauvar; Rolf Lefering; Charles E Wade
Journal:  J Trauma       Date:  2006-06

Review 7.  Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.

Authors:  Anthony E Pusateri; Richard B Weiskopf; Vikhyat Bebarta; Frank Butler; Ramon F Cestero; Irshad H Chaudry; Virgil Deal; Warren C Dorlac; Robert T Gerhardt; Michael B Given; Dan R Hansen; W Keith Hoots; Harvey G Klein; Victor W Macdonald; Kenneth L Mattox; Rodney A Michael; Jon Mogford; Elizabeth A Montcalm-Smith; Debra M Niemeyer; W Keith Prusaczyk; Joseph F Rappold; Todd Rassmussen; Francisco Rentas; James Ross; Christopher Thompson; Leo D Tucker
Journal:  Shock       Date:  2013-02       Impact factor: 3.454

8.  Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation.

Authors:  Yosuke Okamura; Yoshihito Fukui; Koki Kabata; Hidenori Suzuki; Makoto Handa; Yasuo Ikeda; Shinji Takeoka
Journal:  Bioconjug Chem       Date:  2009-09-29       Impact factor: 4.774

Review 9.  Factor VIIa (recombinant) for acute traumatic hemorrhage.

Authors:  Asad E Patanwala
Journal:  Am J Health Syst Pharm       Date:  2008-09-01       Impact factor: 2.637

Review 10.  Intravenous hemostats: challenges in translation to patients.

Authors:  Margaret Lashof-Sullivan; Andrew Shoffstall; Erin Lavik
Journal:  Nanoscale       Date:  2013-10-02       Impact factor: 7.790

View more
  4 in total

Review 1.  Hemostasis and nanotechnology.

Authors:  Patrick Hangge; Jonathan Stone; Hassan Albadawi; Yu Shrike Zhang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 2.  Peptide-based topical agents and intravenous hemostat for rapid hemostasis.

Authors:  Snehasish Ghosh; Archana Tripathi; Paramita Gayen; Rituparna Sinha Roy
Journal:  RSC Med Chem       Date:  2020-10-08

3.  Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma.

Authors:  Chimdiya Onwukwe; Nuzhat Maisha; Mark Holland; Matt Varley; Rebecca Groynom; DaShawn Hickman; Nishant Uppal; Andrew Shoffstall; Jeffrey Ustin; Erin Lavik
Journal:  Bioconjug Chem       Date:  2018-07-09       Impact factor: 4.774

Review 4.  Hemostatic agents for prehospital hemorrhage control: a narrative review.

Authors:  Henry T Peng
Journal:  Mil Med Res       Date:  2020-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.